Protillion Biosciences

Protillion Biosciences is a private, pre-revenue biotech platform company pioneering a high-throughput, quantitative protein characterization technology to revolutionize antibody discovery. The company's core innovation lies in applying NGS-like scale and data generation to the protein level, enabling the simultaneous analysis of millions of protein variants to identify optimal therapeutic candidates. Backed by leading venture capital firms like ARCH Venture Partners and Illumina Ventures, including a $18 million financing round in 2022, Protillion is building a platform that could significantly accelerate and improve the success rate of biologic drug development. The company is in a pre-clinical stage, developing its proprietary technology and likely engaging in early discovery partnerships.

Integrated platform for high-throughput, quantitative protein characterization. Combines library encoding, proprietary protein analysis chips, and machine learning to screen millions of protein variants simultaneously for affinity, specificity, and developability.

Competition includes established antibody discovery service providers (e.g., AbCellera, Twist Biosciences' subsidiary), well-funded startups in high-throughput protein engineering (e.g., BigHat Biosciences, Gensaic), and internal efforts at large pharmaceutical companies. Differentiation hinges on the unique integration of hardware, assays, and data scale.